RxDoctor Payments DataLook up a doctor →

Brad Lerner, MD

Urology · Baltimore, MDNPI 1558346809

Payments from drug & device makers

$20,184in general payments, 2019–2025

Across 403 payments — averaging $50.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SN Holdings, LLC$4K
  • Boston Scientific$3K
  • Johnson & Johnson$2K
  • Urogpo LLC$1K
  • Teleflex LLC$1K
  • Astellas Pharma US Inc$998
  • plus $8K from 50 others

What the payments were for

  • Consulting fees$2,40012%
  • Speaking & faculty fees$1121%
  • Travel & lodging$3,60018%
  • Food & beverage$13,72868%
  • Education$3442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,184 in reported general payments places this provider in the 80th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$350,396
Medicare patients
704
Services billed
32,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide41$551,024
OrgovyxRelugolix45$132,054
Abiraterone Acetate12$85,117
MyrbetriqMirabegron70$82,589
GemtesaVibegron54$68,730
Testosterone12$12,658
Silodosin136$12,311
Alfuzosin Hcl ErAlfuzosin Hcl153$3,819
Dutasteride83$2,874
Tamsulosin Hcl148$2,616
Tadalafil11$1,918
Finasteride102$1,716
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl12$1,668
Oxybutynin Chloride ErOxybutynin Chloride43$1,329
Sildenafil Citrate18$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$998$633,613111 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$938$200,78499 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$58$85,11712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 274 urology providers in Maryland.

Other urology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →